Cutamesine (SA-4503) – Kodiac biolabs

Our opinion on this compoundNiche research probe

54/100

Cleanest sigma-1 probe available; real bench utility but modest and mixed clinical results keep the ceiling low

Look, sigma-1 is genuinely interesting biology. It’s not a traditional receptor. It’s a chaperone protein sitting at the mitochondria-associated ER membrane, regulating IP3 receptors, calcium transfer between organelles, and cellular stress responses. When a compound engages sigma-1, you’re not turning a GPCR on or off. You’re modulating a protein that helps the cell manage ER stress and mitochondrial calcium homeostasis. Thats a different kind of pharmacology, and it opens angles that conventional receptor agonism doesn’t reach.

SA-4503 is the cleanest tool you can buy for studying that biology. Ki of roughly 17 nM at sigma-1 with greater than 100-fold selectivity over sigma-2, and minimal off-target binding beyond that. Most sigma-1 ligands are messy. Fluvoxamine hits sigma-1 but it’s primarily an SSRI, so you can’t attribute any effect cleanly. PRE-084 has been used in academic labs but SA-4503 has become the canonical reference compound precisely because the selectivity story is tight. If your hypothesis is sigma-1 mediated, this is the compound you need to run it cleanly.

Here’s the thing: the clinical picture muddies the enthusiasm considerably. The phase 2 ischemic stroke trial (60 mg, starting within 72 hours, 28 days) showed modest improvement. The MDD phase 2 results were mixed. We don’t see the kind of signal here that makes an investigator want to restructure a research program around the target. Sigma-1’s role in neuroprotection has generated decades of preclinical work and the bench-to-clinic arrow is weaker than the mechanistic story implies. That gap is real and honestly we don’t have a clean explanation for it yet.

What keeps the score from dropping further is exactly that bench utility. Sigma-1 has been pulled into COVID-19 biology (the virus binds sigma-1 through the ORF9c protein), neurodegeneration, addiction circuits, and pain processing. If you’re running any of those programs and you want a clean pharmacological probe to dissect sigma-1 contribution, SA-4503 is irreplaceable. It’s not that the compound is exciting in the way that a novel triple agonist or a mitochondrial peptide is exciting. It’s that for a specific class of research questions, its the only rigorous tool.

We think this lands firmly in niche-probe territory. Dont buy it unless sigma-1 is already in your hypothesis. If it is, dont buy anything else.

Novelty: 40
Mechanism promise: 60
In-category differentiation: 68
Evidence quality: 50
Translational signal: 38
Research bench value: 72

Rationale SA-4503 scores primarily on differentiation and bench value: it’s the canonical selective sigma-1 agonist and nothing else comes close on selectivity, which matters if you’re running a sigma-1 program. But the sigma-1 story is decades old, phase 2 results in both stroke and MDD were modest to mixed, and the indication space is specialized enough that most investigators won’t touch it unless sigma-1 is already in their hypothesis.

Selective sigma-1 receptor agonist

A selective sigma-1 receptor agonist developed for ischemic stroke recovery and major depressive disorder.

Abstract

Cutamesine (SA-4503; CAS 165377-44-6; molecular formula C19H30N2O2; molecular weight 318.45) is a selective sigma-1 receptor agonist developed at Santen Pharmaceutical and licensed to M’s Science. The compound has high sigma-1 affinity (Ki approximately 17 nM) with greater than 100-fold selectivity over sigma-2 and minimal off-target binding. Sigma-1 is a chaperone protein at the mitochondria-associated ER membrane that modulates ion channels, calcium signaling, and stress response. Phase 2 trials in ischemic stroke recovery (60 mg, 28 days starting within 72 hours of stroke) showed modest improvement; phase 2 in MDD showed mixed efficacy. Plasma half-life is approximately 5 hours. The compound is the cleanest available research probe for sigma-1 pharmacology. Used as the canonical selective sigma-1 agonist in academic research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-332Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.